Premium
Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity
Author(s) -
Plonowski Artur,
Varga Jozsef L.,
Schally Andrew V.,
Krupa Magdalena,
Groot Kate,
Halmos Gabor
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10221
Subject(s) - vasoactive intestinal peptide , endocrinology , medicine , somatostatin , antagonist , prostate , receptor , hormone , growth hormone–releasing hormone , peptide hormone , growth factor , chemistry , biology , neuropeptide , cancer , growth hormone
Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone‐releasing hormone (GH‐RH) show considerable homology and are found in prostatic and other carcinomas. Among various analogs of GH‐RH synthesized, JV‐1‐52 is a non‐selective VIP/GH‐RH antagonist, whereas JV‐1‐53 is a VIP antagonist devoid of GH‐RH antagonistic effect. In our study, nude mice bearing PC‐3 human androgen‐independent prostate carcinomas were treated with JV‐1‐52 or JV‐1‐53 (20 μg/day, s.c.) for 28 days. Both antagonists produced a similar reduction in tumor volume (62–67%, p < 0.01) and tumor weight (59–62%; p < 0.05) vs . controls and extended tumor doubling‐time from 9.1 to about 16 days ( p < 0.05). To investigate the mechanisms involved, in another study we compared the effects of JV‐1‐53 with those of somatostatin analog RC‐160. VIP antagonist JV‐1‐53 reduced tumor weight by 67% ( p < 0.01) and suppressed the expression of mRNA for c‐ fos and c‐ jun oncogenes by about 34% ( p < 0.05), without affecting serum levels of insulin‐like growth factor‐I (IGF‐I). In contrast, RC‐160 (50 μg/day) reduced serum IGF‐I by 19% ( p < 0.05), but did not significantly decrease tumor weight. mRNA for VIP and high affinity receptors for VIP were detected on PC‐3 tumors. Our results suggest that VIP/GH‐RH antagonists can inhibit the growth of androgen‐independent prostate cancer by abrogating the autocrine/paracrine mitogenic stimuli of VIP. The ability of GH‐RH antagonists to block tumoral VIP receptors, in addition to GH‐RH receptors, could be potentially beneficial for prostate cancer therapy. © 2002 Wiley‐Liss, Inc.